Clinical trial

Phase III COLLECT study

A placebo-controlled, double-blind, randomized, study to assess the efficacy and safety of Kappaproct® as an add-on to current practice in chronic active treatment refractory UC patients.

Study size
120 subjects randomized.

Countries
Czech Republic, Germany, Hungary, Italy, Poland and UK.

Dosing regime
Two doses of 30 mg 4 weeks apart.

Primary Objective
Clinical remission at week 12.

Secondary Objectives
Time to / rate of colectomy and safety / tolerability during 12 months

For more information about the study, please visit here.